

Index

- 75/75 rule 377–8
- absorption process of body 338, 453
- accidental bias 142
- ACE inhibitor 454
- ACES (active control equivalence studies)
235–50, 454
about ACES 235–7
add-on-trials 247
Bayesian formulation 239
blinding 242–3
and clinically relevant difference 240–1
competence of trials 239
ethical case for 246–7
and evidence of equivalence 237–9
gold-standard trials 239–40
incentive to excellence 242
indirect placebo comparison 244
prespecifying the noninferiority
margin 243
and proof of equality 240
and sample size determination 241–2
sample size equations 249–50
scales of equivalence 245–6
superiority/noninferiority switching
243–4
- activities of daily living requirements 208
- adaptive designs 86, 295, 454
- add-on-trial 247, 454
- addition rule 44, 454
- additivity
about additivity 39
and bioequivalence 371
log-AUCs 368–9
log scale 114
logit scale/transformation 114–16, 119
and measurement of effects 114–16
probability scale 114
residuals 116
- adequate representation, definitions
134–5
- ADEs (adverse drug experiences/events)
384, 392–3, 395, 454
dose response 395–6
- ADI (autosomal dominant inheritance) 435
- ADROIT system 399
- ADRs (adverse drug reactions) 384, 385,
393–4, 395, 454
Type A adverse reactions 384, 454
Type B adverse reactions 384, 454
- adverse drug experiences/events *see* ADEs
(adverse drug experiences/events)
- adverse drug reactions *see* ADRs (adverse
drug reactions)
- alleles 434, 454
- allocate based on covariates (ABC) 61
- allocation of treatments
about treatment allocation 69–71
balance 73–6
bandit designs 85–6
blinding 70, 86–7
blinding problems 86–7
comprehensive cohort designs 84
cut-off designs 80–3
healer/scientist dilemma 69
informed consent 71–2
minimization 77–80
placebo run-ins 71–2
placebos as comparators 72–3
'play the winner' trials 85–6, 92–3
randomization 73–6
randomization issues 70–1
stratification 76

- alpha postulate 206
- alpha-spending approach 454
 - sequential trials 298–9
- alternative hypothesis 48–50, 184–6, 206–7, 454
- analysis
 - and reporting 62
 - safety data 388
- analysis of covariance 38, 96–7, 101, 454–5
 - and baseline errors 104
 - and baseline/outcome relationship 102
 - and change scores/raw outcomes 109–10
 - and correlation of covariates 103
 - and covariate/outcome relationship 108
 - and propensity score 107
- analysis of variance 455
- animal studies, purpose 2
- anticipation, and protocol 57
- Arbuthnott, John (1667–1753) 14
- ARI (autosomal recessive inheritance) 435
- assessment, single case causality 386
- assurance 455
- Atkinson's proposals, minimization 80
- AUC (area under curve) 339, 345–6, 455
 - bioequivalent trials/studies 350, 361–2, 364, 366
 - log-AUCs 346, 368–9
- autosomal dominant inheritance (ADI) 435
- autosomal recessive inheritance (ARI) 435

- balance
 - in allocating treatments 73–6
 - imbalance effects 99–100
 - and randomization 99
- bandit designs 85–6, 455
 - dose-finding 328
- baselines
 - about baselines 95
 - and analysis of covariance 96–7, 101, 104
 - and balance 74
 - balance and randomization 99
 - baseline balance testing 98–9
 - baseline comparisons 29, 455
 - baseline risk
 - meta-analysis 266
 - and regression to the mean 271–2
 - cannot define effects 101
 - choosing to fit 111–12
 - and clinical relevance 100–1
 - define before treatments 104–5
 - and imbalance 99–100
 - Lord's paradox 106–7
 - and multiple covariates 102–3
 - percentage change as a measure 101–2
 - relationship with outcome 102
- Bayes, Thomas (1701–1761) 15–16
- Bayesian statistics
 - about Bayesian statistics 456
 - analysis of safety data 388–9
 - argument against for clinical trials 46–7
 - basic principles 45–6
 - Bayes' theorem 15–16, 45, 455–6
 - bioequivalence studies 376–7
 - carry-over 284
 - causality approaches 399
 - on equivalence trials 239
 - and likelihood probabilities 46
 - meta analysis 261–2
 - multicentre trials 229–30
 - and multiplicity 159–60
 - on one/two sided tests 186
 - over-running trials 309
 - and prior probabilities 46
 - and sample size 204
 - sample size 210
 - selection paradoxes 159–60
 - sequential trials 300–1, 308
 - single-case causality assessment 397
 - stage probabilities 423
 - subgroup issues 137–8
 - subjective nature 47
 - versus frequentist 5, 18, 21, 51
- benefit, and safety 383
- Bernoulli
 - Daniel I (1700–1782) 14
 - James (1654–1705) 13–14
 - Nicholas II (1687–1759) 14
- Bernoulli trials 456
- Bernoulli's weak law of large numbers 13
- bias 456
 - bias-variance trade-off 456–7
 - dose-finding 325
 - biased coin approach (Efron) 73
 - with blinding 37
 - with concurrent controls 34
 - publication bias 256–7
 - with representation of groups 138, 139–40
 - result manipulation 257
 - sequential trials 307–8
 - and Simpson's paradox 142

- binary outcome 457
- binomial distribution 457
 - early work 13
- bioavailability 339, 457
- bioequivalent studies/trials 236, 361–78, 457
 - 75/75 rule 377–8
 - about bioequivalent studies 361–2
 - AUC 361–2, 364, 366, 368–9
 - Bayesian approaches 376–7
 - and blinding 378
 - carry-over adjustment 378
 - confidence intervals 373–5
 - confidence limits 362, 365–6, 372–5
 - equivalence limits 364–5
 - homoscedasticity 369–70
 - Kullback–Leibler (KL) approach 367–8
 - log-transformation versus Fieller’s theorem 368
 - and parallel assay 331
 - power approach 365
 - prescribability 370–1
 - side effects 363
 - switchability issues 371–2
 - treatment version problems 362–4
 - variability of formulations 370–1
- bioinformatics 433, 447
- biometrics 17, 457
- biostatistician 457
- biostatistics 457
- bivariate distribution 31
- blinding
 - in ACES 242–3
 - and allocating treatments 70
 - and bioequivalence 378
 - blinded trials 34–5
 - cut-off designs 81
 - dose-finding 326
 - n*-of-1 trials 292–3
 - placebo-controlled trials 36–7
 - and treatment allocation 86–7
 - un-blinding and sequential trials 310
- block 458
- Bonferroni approach, sequential trials 298
- Bonferroni corrections 151–3, 162–3
- boundary approach, sequential trials 296–7, 458
 - Christmas tree boundaries 297
 - continuous framework 297
- calculus, Bernoulli’ development 13
- carry-over
 - about carry-over 275–7
 - Bayesian approach 284
 - bioequivalence 378
 - definition 458
 - and dose-finding 321
 - eliminating 278–80
 - periods 280, 283
 - problem for cross-over trials 277
 - single/multidose cross-overs 282–3
 - testing for 277–8
 - time issues 280
 - two-stage procedure 280–2
 - weighting issues 278–9
- case-control studies 385–6, 458
- case series approach 399
- causality
 - assessment, single-case 396–8
 - cause of effects problems 401–2
 - and the counterfactual argument 28–9
 - establishment 392
- censored values/information 387, 458–9
- chance, and *n*-of-1 trials 287–8
- change-over design 459
- chemical markers 166
- chi-square tests/statistics 17, 252
- Christmas tree boundaries 297
- circadian rhythms 354
- clearance 339, 353, 357, 459
- clinical relevance, and baselines 100–1
- clinical trials
 - about clinical trials 27–8
 - analysis and reporting 60–1
 - and baseline comparisons 29
 - bias problems 34
 - blinded trials 34–5
 - blinding 36–7
 - comparator/strategy choice 410–11
 - concomitant observations 37–8
 - concurrent controls 33–4
 - counterfactual argument 28–9
 - covariance 38
 - cross-over trials 34
 - and data generation models 39–41
 - defining effects 28
 - discriminatory trials 134
 - with historical controls 29
 - history 20–1
 - hypothesis testing 48–9
 - identifiability 439–40
 - measuring treatment effects 38–9

- clinical trials (*Continued*)
- objectives 27–8
 - parallel-group design 33
 - performing difficulties 61
 - placebo use 34
 - purpose 69
 - randomized clinical trials (RCTs) 34–6
 - economic evaluation 407–9
 - and regression to the mean 33
 - sample size 59–60
 - statistician's role 2–3, 20–1
 - and utmost good faith 35
 - veiled trials 37
 - see also* allocation of treatments; protocol
 - for trials; regression to the mean;
 - sample size; subgroups for trials;
 - two-sided tests
- clinical/statistical relevance 119–20
- clinically relevant difference 48, 459
- with ACES 240–1
 - concept 60
 - and precision 415
 - with sample size 196, 199–206, 208
- closed test procedure 158, 459
- C_{\max} 366–8, 459
- Cochrane collaboration (CC) 257–8
- cohort designs, comprehensive 84
- cohort studies 386–7, 402, 459
- controls for 390–1
- Committee for Proprietary Medicinal Products
- see* CPMP (Committee for Proprietary Medicinal Products)
- comparators
- choosing 410–11
 - placebos for 72–3
- competence of equivalence trials 239–40
- compliance problems *see* intention to treat
- comprehensive cohort designs 84
- concentration
- C_{\max} 366–8
 - of doses 333–4, 350–1
 - over time 340–2
 - plasma concentration 338–9
 - in randomized trials 356–8
- concomitant observations, clinical trials 37–8
- concurrent controls
- clinical trials 33–4
 - definition 459
 - parallel-group design 33
- conditional probability 44–5, 163, 460
- confidence intervals 50, 373–5, 459–60
- symmetric confidence interval approach 375
- confidence limits 50
- bioequivalent trials 362, 365–6, 372–3
- confounders 386, 460
- conjunctive power 209, 460
- consonance 158
- CONSORT statements/recommendations 384, 392, 460
- continual reassessment method *see* CRM (continual reassessment method)
- continuous observations 460
- contrast 461
- control 461
- correlated observations, *n*-of-1 trials 292
- cost(s)
- cost and probability architecture 420
 - cost-benefit analysis 407, 460
 - cost-consequence analysis 407, 460
 - cost-effectiveness analysis 407, 460
 - cost-effectiveness curve 417
 - cost-effectiveness ratios 415–17
 - cost-minimization analysis 407, 460
 - cost-utility analysis 407, 460
 - development costs 423
 - measurement issues 412–13
 - measurement of outcomes 413–14
 - responsive pricing 427
 - and sample size 210
 - standard error calculations 416
 - unit costs 412–13
 - use costs 412–13
 - see also* pharmaco-economics
- counterfactual
- argument 28–9
 - counterfactually thinking 39
 - and post-rescue 178
- covariance, analysis of 38, 100
- covariates
- about covariates 95–7
 - balance and conditioning 74
 - and baseline/outcome relationship 102
 - and baselines 98–100
 - correlation of 103
 - dichotomous 38
 - factors, and allocating treatments 75–6
 - imbalance 99
 - multiple covariates 102–3
 - see also* analysis of covariance
- Cox regression 388, 461
- CPMP (Committee for Proprietary Medicinal Products) 3

- credible intervals 51, 461
 CRF (case record form) 461
 critical regions, in clinical trials 49
 CRM (continual reassessment method) 319,
 328–9, 460
 starting doses 329
 cross-over trials
 about cross-over trials 273–5
 definition 461
 and dose-finding 321
 with gene-by-treatment interaction
 440–1
 latin squares 274
 patient-by-treatment interaction 282
 period, meaning of 283–4
 and randomization 34
 see also bioequivalent studies/trials;
 carry-over
 CTA (Clinical Trial Authorization) 461
 cumulative dose studies, dose-finding
 324–5
 cumulative probability density function
 393, 461
 cut-off designs 80–3
 and blinding treatment 81–2
 efficiency 89–92
 efficiency concerns 82
 modelling issues 81
 and observed covariates 80–1
 and randomized design 83
 regression discontinuity design 82–3
- data analysis preview 61–2
 data cleaning 461
 data-clean certificate 62
 data collection preview 61
 data generation models 39–41
 data-mining in pharmacovigilance
 399–401
 data-monitoring boards (DMBs) 302
 date of information problem (DIP) 261
 decision analysis 52
 decision theory 51–2
 deep structure 98
 degrees of freedom 349
 demographic characteristics 95
 demographic subgroups
 about demographic subgroups 133–4
 discriminatory trials 134
 see also subgroups for trials
 denominators 395
 design-based inference 40
- diapeutics 448
 dichotomizing continuous measurement
 120–1
 dichotomous phenotype 436
 disappointing trial issues 140
 disconnected treatment approach 319–20,
 330
 discrete observations 461
 discriminatory trials 134
 disease incidence 387–8
 disease prevalence 387–8
 disjunctive power 152, 461
 distribution, pharmacokinetics 461
 distribution function 90, 231, 462
 distribution process of body 338
 dose
 definition 333–4
 dose metameter 319, 442, 462
 dose-escalation 318, 321–2
 dose-independent (linear) drugs 340
 dose-proportionality 339–40, 345–7
 dose-response 320–1
 loading dose 340
 response of ADEs 395–6
 dose-finding
 about dose-finding 317–19
 bandit designs 328
 bias-variance trade-off 325
 blinding 326
 and carry-over 321
 continual reassessment method (CRM)
 319, 328–9
 and cross-over 321
 cumulative dose studies 324–5
 direct/indirect assays 318
 disconnected treatment approach
 319–20, 330
 dose metameter 319, 442, 462
 dose-escalation 318, 321–2, 462
 dose-response studies 325
 efficacy/harm/benefit studies 332–3
 factorial design 318
 free combination therapy 318
 maximum-tolerated dose 317, 331
 maximum useful dose 318
 minimum effective dose 317, 331
 monotonicity assumptions 332–3
 multiple testing 322–4
 O'Quigley's continual reassessment
 method 327–8
 parallel assay design 318, 331–2
 parallel group studies/designs 321

- dose-finding (*Continued*)
 placebo designs issues 325–6
 pooling variances 326–7
 random effect models 320–2
 regression approach 319–20
 response surface designs 318
 response-surface methods 329–31
 steady-state concentration 318
 therapeutic window 317
 trend effects 325–6
 veiled trials 325
- double dummy technique 87, 462
- drug development
 process 1–2
 role of statistics 2–3
- drug monitoring 385, 462
- dummy loading 462
- Dunnett's test 157
- duration of action 353, 462
- economic evaluations
 project evaluation 419–22
 with randomized clinical trials (RCTs)
 407–9
 who to perform? 418–19
see also cost(s); pharmaco-economics
- effect size 258–60, 462
- effects of treatment, definitions 28
- effects of treatment measurement 38–9,
 113–31
 about effects measurement 113
 clinical/statistical relevance 119–20
 dichotomizing continuous measurement
 120–1
 individual response 116–19
 mixed model approaches 124–5
 number needed to treat (NNT) 127–8
 Prentice criterion 126
 sigma divided measures 128–9
 surrogate endpoints 125–6
 titrations 126–7
 trend effects 121–4
see also additivity
- efficacy, and safety 23
- efficacy/harm/benefit studies, dose-finding
 332–3
- electronic monitoring 166
- elimination process of body 338, 462
- elimination rate constant 341, 462–3
- E_{\max} model 342
- EMA (European Medicines Agency) 3, 463
- entry criteria 175
- equivalence limits, bioequivalent trials
 364–5
- equivalence trials/studies *see* ACES (active
 control equivalence studies);
 bioequivalent studies/trials
- ethics
 and ACES 246–7
 and protocol 57
 representation of subgroups 137
- European Medicines Agency *see* EMA
 (European Medicines Agency)
- evaluations *see* economic evaluations; project
 evaluation and prioritization
- evidence of equivalence 237–9
- exchangeability, sequential trials 309
- experimental studies 386
- experiments, about experiments 56
- exponential distribution 392, 463
- factorial design 318, 463
- false discovery rate (FDR) control 160–1
- false inclusions 175–6
- family-wise error rate (FWER) 149, 160–1
- FDA (Food and Drugs Administration) 3,
 463
 two-trials rule 188–90
- Fermat, Pierre (1601–1665) 12–13
- Fieller's theorem 368, 417
- first-in-humans problems 402–3
- Fisher, R.A. (1890–1962) 17–18
- Fisher's exact test 184
 improving 191
- Fisher's hypothesis testing 49
- fixed combination therapy 463
- fixed-effect/random-effect models, multicentre
 trials 224–5
- flexible designs controversies, sequential trials
 310–13
- Food and Drugs Administration *see* FDA
 (Food and Drugs Administration)
- footprint 353
- free combination therapy (or drug) 318,
 463
- frequentist statistics 464
 basic principles 47–8
 and hypothesis testing 48
 null hypothesis 48
 subgroup issues 138
 versus Bayesian statistics 5, 18, 21, 51
- futility 464
 stopping for 300

- Galton, Francis (1822–1911) 16–17
- general and generalized linear models 343–4
- genetics 434–7
- alleles 434
 - autosomal dominant inheritance (ADI) 435
 - autosomal recessive inheritance (ARI) 435
 - dichotomous phenotype 436
 - gene-based therapy, economic case 448–50
 - gene-by-treatment interaction 440–1
 - genetic variability 437–9
 - genome 434
 - genotype 434
 - genotypic score 441–5
 - genotyping patients 428
 - Hardy–Weinberg (H-W) equilibrium 436–7, 445
 - heterozygous individuals 435
 - homozygous individuals 434
 - loci 434
 - penetrance 436
 - phenotype 434
 - phenotypic response 435–6
 - whole-genome matching 441
 - see also* pharmacogenetics (and pharmacogenomics)
- GENSTAT package 344
- geometric distribution 392, 464
- Glass effect size 259
- GLIM programming language 343–4
- global multivariate tests 153–4
- global null hypotheses 158
- global univariate tests 154
- glossary 453–80
- gold-standard trials 239–40
- good clinical practice 464
- group sequential method/trials 297–8, 464
- H-W (Hardy–Weinberg) equilibrium 436–7, 445
- half-life (of elimination) 341, 464
- Hardy–Weinberg (H-W) equilibrium 436–7, 445
- harms 384, 464
- hazard
- Cox regression 388
 - hazard rate 388, 392–3, 465
 - proportional hazard model 388
 - heterozygous individuals 435
 - hierarchical generalized approach (HGLM) (Lee and Nelder) 291
 - Hill equation 342
 - historical controls 465
 - Holm's procedure 153
 - homoscedasticity 369–70
 - homozygous individuals 434
 - Hotelling's T^2 test 153
 - HPB (Health Protection Branch) 465
 - human genetic code *see* genetics
 - hypothesis
 - alternative hypothesis 454
 - see also* null hypothesis - hypothesis test/testing 465
 - in controlled clinical trials 48–9
 - and frequentist statistics 48
- ICH (International Conference on Harmonisation) 3, 237, 465
- imbalance with baselines 99–100
- imputation, single/multiple 174–5, 180–1
- incidence of disease 387–8, 465
- IND (Investigation New Drug) application 465
- independence 465
- independent events 44
- individual null hypotheses 158
- individual response measurement 116–19
- inference 51
- design-based inference 40
 - inferential models 40
 - inferential statistics 422
 - and protocol 57
 - randomization-based 40
- informed consent 71–2, 465
- intention to treat
- about intention to treat and missing data 165–7
 - causality issues 168–9
 - electronic monitoring 166
 - entry criteria 175
 - false inclusions 175–6
 - Gould's approach to compliance 169, 177
 - last observation carried forward (LOCF) analysis 170–1, 172
 - low-dose, slow-turnover chemical markers 166
 - missing at random 172–4
 - missing completely at random 171–2
 - missing not at random 174
 - models of missingness 170

- intention to treat (*Continued*)
 - multiple imputation 174–5
 - pattern-mixture models approach 169–70
 - and per-protocol analysis 165–6, 168, 177
 - post-baseline correction 174
 - practical difficulties 176
 - rescue medication 177–8
 - Rubin's reasons for missing treatments 169
 - selection models approach 169
 - tetrachoric correlation coefficient 173
 - theoretical justification 167–8
- interactive effects 217, 220–1
 - treatment-by-centre interaction 227
- International Conference on Harmonisation (ICH) 3, 237, 465
- intersection null hypotheses 158
- inverse probability 12

- Jeffreys–Lindley paradox 206
- joint probability 44, 164, 465

- Kaplan–Meier estimator 387, 465
- Kaplan–Meier procedure 466
- Koseisho (Japan) 466
- Kullback–Leibler (KL) approach 367–8

- label invariance, and two-sided tests 185, 466
- laboratory data 384–5
 - normal ranges 385
 - shift tables 385
 - tolerability data 385
- laboratory shift tables 389–90
- lack of compliance *see* intention to treat
- last observation carried forward (LOCF) analysis 170–1, 172
- Latin squares 274, 466
- least-squares approach 265
- life tables 387, 466
- likelihood principle 466
 - sequential trials 303
- likelihood probabilities 45, 46, 466
- Lindley's formulation 376–7
- linear (dose-independent) drugs 340
- linear kinetics 466
- loading dose 340, 466
- locus 467
- log-AUCs 368–9
- log-odds ratio 387, 467
- log scales 114
 - with scales of equivalence 245–6
- log-transformation versus Fieller's theorem 368
- logistic regression 143, 467
- logit scale/transformation 114–16
- Lord's paradox 106–7
- low-dose, slow-turnover chemical markers 166

- manipulation of results 257
- Mann–Whitney–Wilcoxon test 129, 209
- Mantel–Haenszel procedure 252
- marginal probability 467
- maximum likelihood 467
- maximum tolerated dose 317, 331, 467
- maximum useful dose 318
- mean 467
 - log-AUCs 368–9
- mean square error 139–40, 146–8, 467
- measuring treatment effects 38–9
- median 467
 - log-AUCs 368–9
- medical statistics 19–20
- meta-analysis 251–72
 - about meta-analysis 251–3
 - for analysing multicentre trials 265
 - baseline risk 266, 271–2
 - Bayesian 261–2
 - biasing using empirical weights 270–1
 - and Cochrane collaboration (CC) 257–8
 - concurrent control issues 266–7
 - definition 467–8
 - double-counting of trials 258
 - fixed/random-effects 263
 - interpretation of effect sizes 258–60, 270
 - manipulation of results 257
 - and *P*-values 252, 254
 - publication bias 256–7
 - quality indices 265–6
 - random-effect variances 262, 263–4
 - result prediction 253–4
 - sequential 260–1
 - with sigma divided measures 129
 - two-trials rule 267
 - type A 251
 - type B 252
 - type C 252
 - weighting studies in fixed-effect 264
 - weighting used observed variances 264–5
- see also* pooling

- MHRA (Medicines and Healthcare products Regulatory Agency) 468
- minimization
 Atkinson's proposals 80
 definition 468
 efficiency 89–92
 and treatment allocation 77–80
- minimum effective dose 317, 331, 468
- missing data *see* intention to treat
- mixed model approaches 124–5
- models/modeling
 data generation models 39–41
 fixed-effect/random-effect models 224–5
 general linear models 343
 generalized linear models 343–4
 model-based inference 40
 for multiplicity 154–5
 nonlinear models 343–5
 PD modelling 347–8
 (PK/PD) 337–58
 population designs and models 351–3
 random effect models 320–2, 348–51
- monitoring committees/sponsor conflicts 306
- monotonicity assumptions, dose-finding 332–3
- mortality information/rates 387
 standardized mortality ratio 388
- multicentre trials
 about multicentre trials 213
 Bayesian analogues 229–30
 efficiency with unequal numbers 215
 estimator formulae 231–2
 exploitation of centre to centre effects 228–9
 fixed-effect/random-effect models 224–5
 fixed/random-effect estimators 222–4
 individual centre studies? 225–6
 interactive effects 217, 220–1
 meta-analysis 265
 numbers of patients issues 214
 numbers per centre equality 213–15
 power single/multicentre trials 233
 power and treatment-by-centre interaction 227
 probabilities of effect reversals 233
 recovery of inter-centre information 228
 recruitment formulae 231
 type II/type III sums of squares usage 215–22
- multiple dose studies 282–3, 468
- multiple imputation 174–5
- multiple outcome requirements 208–9
- multiple testing, dose-finding 322–4
- multiplication rule of probability 44, 455, 468
- multiplicity
 about multiplicity 149–50
 Bayesian selection paradoxes 159–60
 Bayesian statistics issues 159
 and Bonferroni corrections 151–3, 162–3
 closed test procedure 158
 and disjunctive power 152
 and error rate control 155
 false discovery rate (FDR) control 160–1
 family-wise error rate (FWER) 149, 160–1
 global multivariate tests 153–4
 Holm's procedure 153
 initial global tests 155–6
 modelling solutions 154–5
 per comparison error rate (PCER) 160
 for quality-of-life assessments 151
 and sample size 208–9
 and significant tests 150
 structured testing 157–9
 and type I errors 150–2, 155–9, 163–4
 and using prespecified outcomes 155
- multivariate analysis 154
- multivariate tests, global 153–4
- mutually exclusive events 44, 468
- n*-of-1 studies/trials
 about *n*-of-1 trials 287–8, 468
 blinding 292–3
 correlated observations 292
 and *P*-values 289–90
 and random-effects analysis 290–2
 stage to use 289
- named patient basis 305, 468
- National Institute for Clinical Excellence (NICE) 406
- National Institutes of Health (NIH) Revitalization Act 134
- NDA (New Drug Application) 469
- Newman-Keuls test 157
- Neyman–Pearson hypothesis testing 49–50, 158, 184
- Neyman–Pearson lemma 421
- NICE (National Institute for Clinical Excellence) 406
- NLIN (SAS) procedure 344
- NNT (numbers needed to treat) 127–8, 429, 469

- nominal significance level 59
- noninferiority margins/trials 241
- nonlinear models 343–5
 - and subgroups for trials 143–4
- NONMEM (SAS PK/PD) package 344
- nonparametric analysis 108, 129, 368, 469
- normal distribution 469
- normal ranges, laboratory data 385, 469
- null hypothesis
 - in clinical trials 48, 158
 - definition 469
 - and evidence 238
 - and homoscedasticity 369–70
 - and *P*-value 206–7
 - and the power approach 365
- numbers needed to treat (NNT) 127–8, 429, 469
- numerators
 - for patients or events 395
 - under-reporting 394–5
- observational studies 386
- Occam's razor 39
- odds 44, 469–70
 - log-odds ratio 387
 - odds ratio (OR) 387, 470
- one-sided tests 184–5
 - bioequivalent trials 375
- one-trial strategy 411
- onset of action to be rapid 358
- option 470
- O'Quigley's continual reassessment method 327–8
- OR (odds ratio) 387
- ORACLE primary database 62
- ordered categorical variable 470
- ordinary least-squares 122–3, 470
 - weights 451–2
- organization, and protocol 57–8
- outcome, measurement 413–14
- over-running, sequential trials 308–9
- overviews *see* meta-analysis
- P*-values
 - about *P*-values 49–50, 183–4, 470
 - and meta-analysis 252, 254
 - and *n*-of-1 trials 289–90
 - and one/two-sided tests 187
 - and replication probabilities 190–1
 - and sample size 204–6
- parallel assay design/trial 470
 - dose-finding 318, 331–2
- parallel group studies/designs/trials 33, 321, 470
- parameter 470–1
- Pascal, Blaise (1623–1662) 12
- Pascal's triangle 12–13
- patent lapse 363, 372
- patient diary 471
- patient-by-treatment interaction 282
- Pearson chi-squared tests 17
- Pearson correlation coefficient 17
- Pearson index (PI) 421, 425–6
- Pearson, Karl (1857–1936) 17
- penetrance 436
- per comparison error rate (PCER) 160
- per-protocol analysis 165–6, 168
 - practical difficulties 177
 - see also* intention to treat
- period, with cross-over trials 283–4
- pharmaceutical statistician, role of 55–65
- pharmaco-economics
 - about pharmaco-economics 405–7
 - information or decisions 409–10
 - numbers needed to treat (NNT) 429
 - and pharmacogenetic subgrouping 426–8
 - precision issues 414–15
 - price-determining/deriving 410
 - standard error calculations 416
 - standard gamble 417–18
 - and trial comparison 410–11
 - who to do evaluation? 418–19
 - see also* cost(s); economic evaluations; project evaluation and prioritization
- pharmacodynamics (PD)
 - about pharmacodynamics 337, 471
 - measure of tolerability 353
 - PD modelling 347–8
 - see also* pharmacokinetic/ pharmacodynamic model (PK/PD); pharmacokinetics (PK)
- pharmacogenetics (and pharmacogenomics) 433–50
 - about pharmacogenetics 433–7, 471
 - cross-over studies with gene-by-treatment interaction 440–1
 - diapeutics 448
 - enrichment studies 448
 - gene-based therapy, economic case 448–50
 - genetic variability 437–9
 - genome 434

- genotypic score 441–5
- identifiability in clinical trials 439–40
- phenotypic response 441–5
- replication 439
- responder/non-responder patients 438
- study design 445–8
- subgrouping 426–8
- theranostics 448–50
- whole-genome matching 441
- see also* genetics
- pharmacokinetic/pharmacodynamic model (PK/PD) 342–3
 - duration of action 353
 - nonlinear models 343–5
 - population designs and models 351–3
 - random-effect model 348–51
 - randomized to concentration trials 356–8
- pharmacokinetics (PK)
 - about pharmacokinetics 337–43, 471
 - absorption 338
 - AUC (area under the curve) 339
 - bioavailability 339
 - clearance 339
 - distribution 338
 - dose proportionality 339–40
 - dose-independent (linear) drugs 340
 - dose-proportionality 345–7, 348
 - elimination 338
 - elimination rate constant 341
 - extraction ratio 339
 - half-life (of elimination) 341
 - loading dose 340
 - pro-drugs 339
 - protein binding 338
 - steady-state concentrations 340
 - studies in 2, 338
 - superposition principle 340
 - volume of distribution 339
 - see also* models/modelling
- pharmacovigilance 2, 385, 386, 471
 - data-mining in 399–401
- phase I studies 2, 471
- phase II studies 471
- phase III studies 2, 471
- phase IV studies 2, 385, 471
- phenotype 434, 471
 - phenotypic response 435–6, 441–5
- Pitman asymptotic efficiency 120–1
- placebos
 - about placebo groups 34
 - with ACES 247
 - and blinding 36–7
 - as comparators 72–3
 - designs issues, dose-finding 325–6
 - and equivalence studies 244
 - run-ins 71–2
 - and informed consent 71–2
 - plasma concentration 338–9
 - 'play the winner' trials/design 85–6, 92–3, 471
 - Poisson distribution 471–2
 - Poisson variables 214
 - pooling
 - about pooling 253
 - different studies 254–5
 - different treatments 255–6
 - Glass effect size 259
 - pooled-trials rule 188–9
 - and sample size 208
 - pooling variances, dose-finding 326–7
 - see also* meta-analysis
 - population concept 472
 - portfolio management *see* cost(s); project evaluation and prioritization
 - post-baseline correction 174
 - post-rescue, and counterfactual 178
 - post-stratification 18, 472
 - posterior probabilities 45–6, 472
 - power
 - bioequivalent studies 365
 - calculations 48–9
 - definition 48, 472
 - multi-centre trials 227
 - and sample size 200, 201, 202, 209
 - single/multicentre trials 233
 - Prentice criterion 126
 - prescribability of formulations 370–1
 - prespecified outcomes, and multiplicity 155
 - prevalence of disease 387–8, 472
 - price-determining/deriving 410
 - responsive pricing 427
 - prior probability concept 45, 46, 472
 - pro-drugs 339, 472
 - probability
 - about probability 44, 473
 - conditional probability 44
 - early probabilists 12–13
 - history
 - early workers 12–14
 - late 17th to early 19th centuries 14–15
 - inverse 12
 - joint probability 44
 - marginal probability 44

- probability (*Continued*)
 posterior probabilities 45–6
 probabilistic law 13
 probability density 392–3, 473
 probability density function 393, 473
 probability distribution 473
 probability mass function 473
 probability scale 114
 probability statements 386
 and statistics 11–12
- proc GLM (SAS) 216, 220
- project evaluation and prioritization 407,
 419–22, 473
 assessing development costs 423
 assessment of probabilities 422–3
 is faster better? 422
 Pearson index (PI) 421, 425–6
 reward assessment 423–4
 risk-reward grid 425–6
 risk/risk diversification 424–6
- propensity score 107
- proportional hazard model 388, 473
- proportional reporting ratio (PRR) 400
- prospective studies 386, 474
- protein binding 338, 474
- protocol exchangeability 254
- protocol for trials 57–8
 planning 58–9
- publication bias, meta analysis 256–7
- QALY (quality-adjusted life years) 414
- qualitative interaction 136
- quality control
 false inclusion 175
 stochastic curtailment 299
- quality indices, meta-analysis 265–6
- quality-of life assessments, and multiplicity
 151
- Quetelet, Adolphe (1796–1874) 16
- quota sampling 135
- racemate 474
- radix of a table 387, 474
- random-effect variances, meta-analysis 262
- random-effects models/analysis
 dose-finding 320–2
 estimates from 263–4
 or fixed effect 224–5, 263
 and *n*-of-1 trials 290–2, 474
 repeated measures 348–51
- random treatment-by-centre interaction
 222–4
- random variable 474
- randomization
 allocate based on covariates (ABC) 61
 and allocating treatments 70–1, 73–6
 and balance 99
 biased coin approach 73
 cross-over trials 34
 and cut-off designs 81
 definition 474
 efficiency 89–92
 post-allocation approach 60–1
 pre-allocation approach 60–1
 randomization-based inference 40
 randomized blocks 70
 and study design 60–1
 and variance 88–9
- randomized clinical trials (RCTs) 34–6
 economic evaluations 407–9
- randomized to concentration trials 356–8
- rank test 474
- raw outcomes, and clinical relevance
 100–1
- RCTs *see* randomized clinical trials (RCTs)
- recovering inter-centre information 228
- recruitment time problems 135–6
 equations for 145–6, 231
- regression approach, dose-finding 319–20
- regression discontinuity design 82–3, 96
- regression to the mean 29–33, 474–5
 about regression to the mean 29–31
 and analysis of covariance 38
 in baseline comparisons 29
 and baseline risk 271–2
 in clinical trials 32–3
 Galton discovery 16
- regulators 1
- regulator's risk 475
 bioequivalent trials 365
 table for 185
- reimbursees 2
- relative risk 386–7, 475
- repeated-measures
 design 475
 mixed models 124–5
 and random effect models 348–51
- repeated testing, sequential trials 302–4
- replication
 pharmacogenetics 439
 probabilities and *P*-values 190–1
- reporting
 and analysis 62–3
 proportional reporting ratio (PRR) 400–1

- rates 391–2
- reporting ratio (RR) 400–1
- under reporting 394–5
- representation in trials
 - Type I, II, III, and IV 135
 - see also* subgroups for trials
- rescue medication 177–8
- residuals 116
 - residual sum of squares 475
- response
 - with hypertension 121
 - response-surface designs/methods 318, 329–31, 475
- responsive pricing 427
- retrospective studies 385, 475
- reversible reaction drugs 340
- reward assessment 423–4
- risk
 - project evaluation 424–6
 - relative 386–7
 - risk-benefit analysis 398–9
 - risk-reward grid 425
- robust statistics 475
- root mean square measure 475
- Royal Statistical Society (RSS) working party 391
- safety of pharmaceuticals
 - about safety 383–8
 - and benefit 383
 - cohort controls 390–1
 - dose response 395–6
 - and efficacy 383
 - first-in-human studies 402–3
 - formal analyses 388–9
 - hazard rate 388, 392–3
 - pharmacovigilance 399–401
 - reporting issues 394–5
 - see also* ADEs (adverse drug experiences/events); ADRs (adverse drug reactions); risk
- sample size
 - about sample size 195–8
 - and ACES 241–2, 249–50
 - adjusting for success 199
 - approximate formula 196
 - problems with 198–9
 - assurance calculation 210–11
 - Bayes theorem 204
 - Bayesian approaches 210
 - calculation issues 199–200
 - conventions used 196
 - cost issues 210
 - determination 59–60
 - example calculation 197–8
 - inputs required 196
 - with multiple requirements 208–9
 - P*-value issues 204–7
 - pooled-trials rule 208
 - and power calculations 200, 201, 202, 209
 - review analysis 301
 - significance with large trials 204
 - small trials unethical 203–4
 - trials unethical if large 203
 - two-trials rule 208
- sample space 475–6
- SAS (Statistical Analysis System) 62, 124, 344, 476
 - and multicentre trials 216–17, 220
- sequential meta-analysis 260–1
- sequential trials 295–313
 - about sequential trials 295–302, 476
 - adaptive designs 295, 302
 - alpha-spending approach 298–9
 - Bayesian procedures 300–1
 - bias adjustment 308
 - defining regions of practical equivalence 301
 - over-running 309
 - with randomization 300
 - Bayesian/frequentist approaches 302–4
 - bias adjustment 307–8
 - Bonferroni approach 298
 - boundary approach 296–7
 - decision/information stopping issues 309–10
 - estimative approach 301
 - exchangeability 309
 - flexible designs controversies 310–13
 - group sequential trials 297–8
 - hypothesis testing approach 301
 - over-running 308–9
 - predictive approach 301
 - relevance 304–5
 - repeated testing adjustment issues 302–4
 - sample size review analysis 301
 - shrinkage 307–8
 - sponsor/monitoring committees conflicts 306
 - stochastic curtailment approach 299
 - stopping for futility 300
 - stopping rules 303
 - two-trials rule 306–7

- sequential trials (*Continued*)
 un-blinding concerns 310
 weighting 312
- serious disease problems 137
- shift tables, laboratory data 385, 389, 476
- shrinkage, sequential trials 307–8
- side effects
 and ADEs 395
 bioequivalent trials 363
 and dose-finding 318
 and risk-benefit analysis 398
 and safety/tolerability 385
- sigma divided measures 128–9
 Mann–Whitney–Wilcoxon test 129
 meta-analysis 129
- significance (tests) 98, 476
 for baseline balance 98–9
 and clinically relevant difference 240
 and drug equivalence 238
 group sequential trials 297–8
 level 48, 59, 200
 and measuring trends 123
 minimum effective dose 331
 and multiplicity 150, 151–2
 and one sided tests 185
 and *P*-values 49–50, 190–1, 204–6
 with price determination 410
 publication bias 256–7
 and sample size 195, 198–9, 206, 208
 and secondary endpoints 155
 two trials rule 188, 188–9, 208
 in two-stage procedure 280–2
- Simpson, John (1710–1761) 15
- Simpson's paradox 141–3
- Simpson's rule 15
- single case causality assessment 386
- single dose studies 2, 282–3, 476
- single imputation method 170, 174–5, 180
- single-case causality assessment 396–8
- size (of a test) 476
see also significance (tests)
- smoothness index 353–5
- SPID (sum of the pain intensity differences
 from baseline) index 151
- sponsors 1
 manipulation of results 257
 monitoring committee conflicts 306
 sponsors risk 477
- standard deviation 118, 477
 with sample size formula 198
- standard error 477
 calculations 34, 416
 reliability estimates 50
- standard gamble 417–18, 477
- standardized mortality ratio 388, 477
- statistical/clinical relevance 119–20
- statisticians
 about statisticians 3
 early 11–20
 pharmaceutical, role of 55–65
- statistics
 about statistics 11–12, 477
 Bayesian versus frequentist 5, 18, 21, 51
 current clinical trials 20–1
 history 11–23
 journals and organizations 22
 lack of unanimity 27
 as a living science 21–2
 medical 19–20
 modern mathematical 18
 and probability 11–12
 research 63–4
 role of 2–3
see also Bayesian statistics; frequentist
 statistics
- steady-state concentration 318, 341, 477
- stochastic curtailment approach 299, 477
- stopping
 for futility 300
 stopping rules 303, 309–10
- stratification
 and covariate information 96–7
 defined 473
 post-stratification 38, 472
 and treatment allocation 76
- structured testing, with multiplicity 157–9
- 'Student' (William Gosset) 17
- Student's *t*-statistic/distribution 17, 49, 478
- subgroups for trials 133–44
 accidental bias 142
 adequate representation of women 134–8
 Bayesian and frequentist approaches
 137–8
 demographic issues 136–7
 demographic quotas 114
 detecting differences between the sexes
 141
 disappointing trial issues 140
 ethical issues 137
 and nonlinear models 143–4
 quota sampling 135
 recruitment time problems 135–6
 separate analyses issues 138–9

- serious disease problems 137
- Simpson's paradox 141–3
- trial demograph fraction 138–9
- summary-measures approach 121–2, 349, 351, 478
- sums of squares, type II and type III 215–22
- superposition principle 340, 478
- surrogate endpoints 125–6
- survival analysis 308, 388, 478
 - origins 15
- Swiss medic 478
- switchability issues 371–2
- symptom free weeks 414

- t*-statistic/distribution 17, 49, 478
- t*-test 17
- T_{\max} 366–8, 479
- Terpstra–Jonckheere test 323
- TESS (treatment emergent signs and symptoms) 389–90
- test of significance, with sample size 198
- test statistics, in clinical trials 49
- tetrachoric correlation coefficient 173
- theranostics 448–50
- therapeutic window 317, 479
- three-period equivalence protocol 372
- time issues 392–4
 - time frames 386
 - time trends 479
 - and baseline comparisons 29
 - T_{\max} 366–8, 479
- titrations 126–7
- tolerability data 479
 - laboratory data 385
- toxicity, and O'Quigley's continual reassessment method 327–8
- transforms 114–16, 343–4
 - log transforms 368–9
 - logit transformation 114–15
- treatment allocation *see* allocation of treatments
- treatment effects *see* effects
- treatment emergent signs and symptoms (TESS) 389–90
- treatment version problems 362–4
- trend effects
 - dose-finding 325–66
 - measuring 121–4
 - summary measures approach 121–2
 - time trends 29
- trial demograph fraction 138–9
- trials *see* clinical trials
- triangular test 309, 479
- trough-to-peak ratios 353–5
- two one-sided tests (TOST) 373–5
- two-sided tests 184–5
 - Bayesian point of view 186
 - and label invariance 185
 - and one-sided tests 185–6
 - P*-value issues 187
 - relevance argument 185
- two-stage procedure
 - and carry-over 280–2
 - CROS test 281–2
 - PAR test 281–2
- two-trial strategy 411
- two-trials rule 188–90
 - meta-analysis 267
 - and the pooled-trials rule 188–9
 - sample size 208
 - sequential trials 306–7
- Type A adverse reactions 384
- type A meta-analysis 251
- Type B adverse reactions 384
- type B meta-analysis 252
- type C meta-analysis 252
- type I error
 - bioequivalent studies 375
 - in bioequivalent studies 365, 375, 377
 - defined 479
 - with hypothesis testing 48–9
 - with inferential statistics 422
 - and multiplicity 150–2, 155–9164
 - sequential trials 297–8
 - two-stage procedure 282
 - and the two-trials rule 188
- type I sums of squares 217, 479
- type II error 48, 49, 479
- type III error 479
- type II–III sums of squares 215–22, 479

- uncontrolled study 479
- uninformative prior concept 51, 480
- unit costs 412–13
- univariate tests, global 154
- use costs 412–13
- utmost good faith 480
 - establishing 35
 - and protocol 57–8
 - randomized clinical trials 418
 - trial reporting 115

- van Huygens, Christian (1629–1695) 12
- variability of formulations 370–1

- variance
 - analysis of variance 455
 - and Bayesian selection 159–60
 - bias–variance trade-off 456–7
 - and correlation coefficient 100
 - cut-off designs 82
 - defined 480
 - with minimization 77–80
 - randomization and balance 73–6
 - and randomized design 88–9
 - and sample size 198
 - and sigma divided measures 128–9
 - with single imputation 180–1
- veiled trials 37, 480
 - dose-finding 325
- virtual risk 237
- visual analogue scale (VAS) pain scores 292–3
- volume of distribution in body 339, 480
- wash-out periods 480
 - bioequivalent trials 361
 - carry-over elimination 280, 283
 - placebo run-in alternative 72
- weighting
 - optimal compromise with subgroups 139–40, 147–8
 - ordinary least-squares weights 451–2
 - sequential trials 312
 - studies in fixed-effect meta-analysis 264
 - with type II or type III sums of squares 217–18
 - used observed variances 264–5
- women, adequate trial representation 134–8
- z-statistics 188

